Firms

re.Mind Capital

Early-stage venture investor focused on mental health, brain health and human flourishing, within Apeiron Investment Group. Direct BCI and neuromodulation exposure is distinct from neuroscience therapeutics, diagnostics and mental-health services.

Founded: —
Type: Venture capital

Funds1

re.Mind first fund——
HTGF co-investor release 2022-01-12 describes USD 150m managed by first fund. No formal final-close date or commitments schedule. This is not evidence of newer fund/current AUM; unsupported USD 650m excluded.

Team

No team members on record yet.

Investments

$18M2024-01-24	Motif Neurotech	Arboretum Ventures, Dolby Family Ventures, KdT Ventures, Satori Neuro, re.Mind Capital, Max Hodak, Divergent Capital, TMC Innovation, PsyMed Ventures, Empath Ventures, Capital Factory
$41M2023-01-25	Precision Neuroscience	Forepont Capital Partners, Mubadala Capital, Draper Associates, Alumni Ventures, re.Mind Capital, Steadview Capital, B Capital
$—2022-01-12	CereGate	468 Capital, re.Mind Capital, TruVenturo, Heal Capital, High-Tech Gründerfonds
$40M2021-06-03	Synchron	Khosla Ventures, Forepont Capital Partners, ID8 Investments, Shanda Group, General Advance, Subversive Capital, re.Mind Capital, Arani Bose, Thomas Reardon, Neuro Technology Investors, METIS Innovative, University of Melbourne
$10M2021-05-19	Blackrock Neurotech	re.Mind Capital, Peter Thiel, Tim Sievers, University Venture Fund II
$—2022-07-28	iLoF	Faber, Lunar Ventures, Alter Global, M12, Scale Venture Partners, Quiet Capital, re.Mind Capital
$—2021-10-07	Neumora Therapeutics, Inc.	ARCH Venture Partners, Catalio Capital Management, F-Prime Capital, Alexandria Venture Investments, Polaris Innovation Fund, re.Mind Capital
$—Unknown date	neurocare group	re.Mind Capital
$—2026-03-02	Neurocast.ai	re.Mind Capital

team@apexlogos.ai10 hours ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities. Fund size and stages | Item | Supported conclusion | Source/date and limits | | --- | --- | --- | | First fund | USD 150 million managed by the first re.Mind fund | [HTGF CereGate financing release](https://www.htgf.de/en/htgf-financing-ceregate/), 2022-01-12. This co-investor announcement describes an operating fund and around 20 portfolio companies; it does not supply a formal final-close date or commitments schedule. | | Earlier founder statement | Christian Angermayer describes a new USD 150m fund funded substantially by himself and other investors | [Founder article](https://www.linkedin.com/pulse/those-who-cannot-remember-past-condemned-repeat-christian-angermayer), 2021-era article, exact day not recovered, accessed 2026-10-06. Consistent with HTGF, not a second fund. | | Newer fund/current AUM | Not verified | Searches for newer funds and a USD 650m claim did not recover a reliable fund announcement. Do not use investee rounds, Apeiron group AUM or the Signal check range as fund size. | | Current mandate | Early-stage investor focused on mental/brain health | [Official root](https://remind.vc/), undated, accessed 2026-10-06. No firm-wide exclusive series boundary stated. | | Historical scope | An investee release says re.Mind invests at any stage; transactions include seed, Series A and Series B | [neurocare financing announcement](https://www.neurocaregroup.com/news-insights/neurocare-announces-financing-round-with-bm-t-and-strategic-investor-apeiron-re-mind), 2020-era release, exact day not recovered, accessed 2026-10-06; dated transactions below. Retain the historical/current distinction. | Funds recorded in Adex after this review: | Fund | Disclosed amount | Announcement / filing date | | --- | --- | --- | | re.Mind first fund | Undisclosed / unverified | Unknown |
team@apexlogos.ai11 hours ago
Match research 2026-10-06 / GoldireMindCapital / sha256:822a8600e822f41c20d3691df73948973f507d87bd46606714e54b80f972ede9 / part 2 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. | **Neurocast.ai** | [Company announcement syndicated by StreetInsider](https://www.streetinsider.com/Press%2BReleases/re.Mind%2Bjoins%2BNeurocast.ai%2Bas%2Binvestor%2Bto%2Badvance%2Bcontinuous%2Bbrain%2Bhealth%2Bmonitoring/26085070.html), dateline 2026-03-02 (US display timestamp March 1), announces re.Mind investment; amount undisclosed. | Brain-health monitoring using passive smartphone behavior/digital biomarkers; neuroscience/digital-health adjacency rather than implanted neural sensing. Source says FDA-registered, which should not be recast as FDA-cleared/approved. Stage not specified. This newer transaction counters stale aggregator inactivity claims. | ## Portfolio-only leads, conflicts and missing information - The [official detailed homepage](https://remind.vc/homepage/) describes additional portfolio technology themes and the [firm’s LinkedIn BCI post](https://www.linkedin.com/posts/remindvc_sxsw-bci-neurotech-activity-7041807725571264513-Xcx6) names Synchron and OpenBCI alongside Blackrock, Precision and CereGate (2023-era post, exact day not recovered, accessed 2026-10-06). Treat Synchron/OpenBCI as direct firm portfolio claims; round/date/check still need verification. Synchron’s [2022 Series C release hosted by investor Reliance](https://www.ril.com/sites/default/files/2023-01/MR15122022.pdf) does not name re.Mind, so do not assign that round from portfolio membership alone. - [Gaebler](https://www.gaebler.com/VC-Investors-0241E0EE-9405-4581-95A4-2DEEE5E41B1F-re-Mind-Capital) (undated, accessed 2026-10-06) labels the firm inactive and has no fund closing recorded. This conflicts with the official live early-stage mandate and 2026 Neurocast announcement; an aggregator status is insufficient to conclude inactivity. - [Capital Atlas](https://capitalatlas.ai/funds/428013) (undated, accessed 2026-10-06) displays USD 650m latest fund and USD 4.2bn AUM without a named fund/vintage/close supporting those numbers. They remain unverified and should not replace USD 150m first-fund evidence. Potential broader-group/investee conflation cannot be resolved from the page. - In the snapshot, iLoF round metadata includes Faber and Lunar-specific evidence attached to a shared round. Those prove neither re.Mind’s check nor its leadership; the independent named investor list resolves participation. Neumora’s goldi.ai/ARCH metadata should be replaced in later review with the official company investor list. - The 2020 founding year appears in directories but was not established by a dated formation record in this review. Current legal fund vehicle, closed commitments, fee-paying AUM, dry powder, next fund, firm-wide check policy and individual checks remain undisclosed/unverified. - Wider Apeiron/Angermayer investments and founder history (including atai/Compass) are not automatically re.Mind investments. Other leads such as Delix, Sensorium and CB Therapeutics need transaction-level verification before importing; official stories/news alone may describe sector news rather than an attributable investment. ## Concrete notes for later Adex review Preserve exact ID `GoldireMindCapital`. Consider official website/description, current early-stage strategy and the dated USD 150m first-fund disclosure with status caveat. Keep the verified Precision/Blackrock participation records and strengthen Neumora/iLoF citations. Review additional CereGate, Motif, neurocare and Neurocast relationships using the sources above, preserving unknown series/checks and brain-health adjacency. Keep Signal check values as attributed profile claims. Do not import unsupported USD 650m fund/AUM or infer a 2022 Synchron round. All external sources were accessed 2026-10-06; publication dates and access limitations are stated above.
team@apexlogos.ai11 hours ago
Match research 2026-10-06 / GoldireMindCapital / sha256:822a8600e822f41c20d3691df73948973f507d87bd46606714e54b80f972ede9 / part 1 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. # re.Mind Capital Research completed: 2026-10-06. Exact Adex ID: `GoldireMindCapital`. Canonical Adex URL: https://adex.page/firms/GoldireMindCapital. This is research for later review; no Adex/database changes were made. ## Identity and summary re.Mind Capital is a venture investor dedicated to mental and neurological health, within Christian Angermayer’s Apeiron Investment Group. Its official detailed homepage names Christian Angermayer, Max de Vere and Jan Hardorp as co-founders/general partners, gives a London office and a Maltese company footer. The root website now describes an early-stage focus on mental health, brain health and human flourishing. This is re.Mind, not the unrelated real-estate business REM Capital, and `Goldi` in the immutable Adex ID is not its brand. Sources: [official root](https://remind.vc/) and [detailed homepage](https://remind.vc/homepage/), undated, accessed 2026-10-06. Strong verified fit: direct BCI and neuromodulation investments in Blackrock Neurotech, Precision Neuroscience, CereGate and Motif Neurotech, alongside scientific drug-discovery/diagnostics exposure. Latest-known supported fund-size disclosure is USD 150 million for its first fund, reported in January 2022; a newer fund size was not verified. ## Starting evidence: Adex and NFX Signal Saved source: `_sources/GoldireMindCapital.adex.json`, retrieved 2026-10-06 at 19:29:05 UTC from read-only Adex MCP Search. The record name is re.Mind Capital; description/founding date are blank, check-size fields null, and no NFX URL is supplied. Its generic source is https://goldi.ai/. Four investment participations are present: Blackrock Neurotech (2021-05-19, USD 10m financing, lead), Neumora (2021-10-07, Series A), iLoF (2022-07-28, seed), Precision Neuroscience (2023-01-25, USD 41m Series B, participant). Snapshot claims are baseline evidence only. NFX was searched for the firm and named founders/team. A generic list led to the directly readable [Signal firm page](https://signal.nfx.com/firms/re-mind-capital-ltd) (undated, accessed 2026-10-06). It locates the firm in London and names Max de Vere, partner, and Joao Barbosa da Silva, investor. Both show USD 100k–5m ranges and USD 1.5m sweet spots, with seed/pre-seed medical devices, biotech, consumer health and digital health categories. These are individual profile claims, not independently verified firm limits. Intro paths require Gmail sign-in. The generic marketing-tech investor-list inclusion is not evidence of a core marketing-tech mandate. ## Fund size and stages | Item | Supported conclusion | Source/date and limits | | --- | --- | --- | | First fund | USD 150 million managed by the first re.Mind fund | [HTGF CereGate financing release](https://www.htgf.de/en/htgf-financing-ceregate/), 2022-01-12. This co-investor announcement describes an operating fund and around 20 portfolio companies; it does not supply a formal final-close date or commitments schedule. | | Earlier founder statement | Christian Angermayer describes a new USD 150m fund funded substantially by himself and other investors | [Founder article](https://www.linkedin.com/pulse/those-who-cannot-remember-past-condemned-repeat-christian-angermayer), 2021-era article, exact day not recovered, accessed 2026-10-06. Consistent with HTGF, not a second fund. | | Newer fund/current AUM | Not verified | Searches for newer funds and a USD 650m claim did not recover a reliable fund announcement. Do not use investee rounds, Apeiron group AUM or the Signal check range as fund size. | | Current mandate | Early-stage investor focused on mental/brain health | [Official root](https://remind.vc/), undated, accessed 2026-10-06. No firm-wide exclusive series boundary stated. | | Historical scope | An investee release says re.Mind invests at any stage; transactions include seed, Series A and Series B | [neurocare financing announcement](https://www.neurocaregroup.com/news-insights/neurocare-announces-financing-round-with-bm-t-and-strategic-investor-apeiron-re-mind), 2020-era release, exact day not recovered, accessed 2026-10-06; dated transactions below. Retain the historical/current distinction. | ## Verified previous deep-tech and direct neurotech investments All round totals below are company-wide financing amounts, not re.Mind’s individual check. Classification is a research interpretation based on the described technology; it does not establish clinical efficacy or regulatory approval. | Company | Investment attribution and date | Technology relevance and caveats | Supporting source | | --- | --- | --- | --- | | **Blackrock Neurotech** | Led closed USD 10m financing announced 2021-05-19; Angermayer and Hardorp joined the board | Direct neurotech and deep tech: implanted electrode arrays/BCI enable communication and control of external devices. No series label provided. | [Official company release](https://blackrockneurotech.com/insights/blackrock-neurotech-closes-10m-financing-round-to-advance-development-of-its-world-leading-brain-computer-interface-bci-technology/), 2021-05-19. Search-index text was readable; direct open initially returned an internal error. | | **Precision Neuroscience** | Named participant in USD 41m Series B led by Forepont, 2023-01-25 | Direct neurotech and deep tech: thin-film cortical microelectrode interface designed for high-resolution brain recording and reversible placement. | [Company-issued GlobeNewswire release](https://www.globenewswire.com/news-release/2023/01/25/2595114/0/en/precision-neuroscience-raises-41-million-to-build-and-scale-the-next-generation-of-treatments-for-neurological-illnesses.html), 2023-01-25, directly read. | | **CereGate** | Co-led financing with 468 Capital, announced 2022-01-12; amount/series undisclosed in source | Direct neurotech: software-based computer-to-brain interface using neuromodulation devices; applications described for deep brain stimulation and spinal cord stimulation. Software here interfaces with neural stimulation hardware rather than ordinary SaaS. | [HTGF official co-investor release](https://www.htgf.de/en/htgf-financing-ceregate/), 2022-01-12. | | **Motif Neurotech** | Named new investor in USD 18.75m Series A led by Arboretum, 2024-01-24 | Direct neurotech and deep tech: miniature DOT brain pacemaker/microstimulator, initially being developed for treatment-resistant depression. | [Transaction counsel Wilson Sonsini announcement](https://www.wsgr.com/print/v2/content/49016904/Wilson-Sonsini-Advises-Motif-Neurotech-on-%2418.75-Million-Series-A-Financing.pdf), document date 2024-01-24; search-index readable. | | **neurocare group** | Company explicitly announces new strategic investor re.Mind and refers to it as an anchor investor; amount/series undisclosed | Direct neuromodulation exposure through personalized clinical care and a DTx platform. A mixed provider/platform investment; distinguish delivery of neurostimulation and neurofeedback from a pure implant/device manufacturer. | [Official neurocare announcement](https://www.neurocaregroup.com/news-insights/neurocare-announces-financing-round-with-bm-t-and-strategic-investor-apeiron-re-mind), 2020-era release, exact day not recovered, accessed 2026-10-06. | ## Verified scientific investments adjacent to direct neurotech | Company | Investment and supporting dates | Classification and attribution | | --- | --- | --- | | **iLoF** | Named re.Mind participant, funding announced 2022-07-28. [EU-Startups reporting](https://www.eu-startups.com/2022/07/digital-health-startup-ilof-secures-e4-89-million-to-accelerate-personalised-drug-discovery/) reports about EUR 4m equity plus EUR 880k ERDF grant, headline EUR 4.89m; [official re.Mind stories](https://remind.vc/stories/) features it on 2022-08-01. | Deep tech: photonics/optical biological fingerprints and AI for biomarker libraries and personalized drug-development screening. Alzheimer’s applications make it neuroscience-adjacent, not a direct BCI or neural stimulation investment. The article mixes currency wording in one sentence; retain approximate EUR figures and separate grant/equity. | | **Neumora Therapeutics** | [Official company launch release](https://neumoratx.com/news/neumora-therapeutics-launches-to-pioneer-a-new-era-of-precision-medicines-for-brain-diseases/), 2021-10-07, explicitly names re.Mind Capital (Apeiron) in the ARCH-led Series A syndicate and reports over USD 500m raised including separate USD 100m Amgen equity. | Deep scientific biotech: precision medicines/data science for neuropsychiatric and neurodegenerative disorders. Neuroscience drug discovery, not direct BCI/neural interface. Do not record the whole USD 500m as re.Mind’s check or assume it is solely Series A. |
team@apexlogos.ai21 days ago
MATCH

Funds1

Team

Co-investing

Investments